{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.52","upperLimit":"12.70","value":"8.42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"Median and range of bortezomib clearance during Induction II.","dispersionType":"Full Range","groups":[{"description":"IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.\n\nIND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.\n\nINT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.\n\nSCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.","id":"OG000","title":"Arm B"}],"paramType":"MEDIAN","populationDescription":"Only eligible patients on Arm B with evaluable Bortezomib PK clearance data during Induction II are reported.","reportingStatus":"POSTED","timeFrame":"Day 8 of Induction II","title":"Bortezomib Clearance","type":"SECONDARY","unitOfMeasure":"Liters/hour/m^2"}